Monoclonal Gammopathy Of Undetermined Significance (MGUS)


Article Author:
Hatem Kaseb


Article Editor:
Hani Babiker


Editors In Chief:
Melissa Max
Danyae Lee
Manouchkathe Cassagnol


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
6/4/2019 7:32:52 PM

Introduction

Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant plasma cell disorder that is characterized by the presence of serum M-protein less than 30 g/L, bone marrow (BM) clonal plasma cells less than 10%, absence of plasma cell myeloma (PCM) related end-organ damage (CRAB symptoms: hypercalcemia, renal insufficiency, anemia and, bone lesions) and absence of B-cell lymphoma or other disease known to produce an M-protein. MGUS is generally considered a preneoplastic disorder that does not always progress to overt malignancy [1]There are 2 distinct types of MGUS [2]

  1. Non-IgM MGUS
  2. IgM MGUS: Non-IgM MGUS (IgG, IgA, IgD or light chain (LC) MGUS) accounts for the majority of MGUS cases and is characterized by a monoclonal plasma cell.

Non-IgM MGUS may progress to a malignant plasma cell neoplasm. IgM MGUS is considered a separate entity by the 2017 WHO classification. IgM MGUS may progress to Waldenstrom macroglobulinemia, immunoglobulin light chain (AL) amyloidosis, or lymphoma. Light chain MGUS is characterized by a monoclonal protein that lacks the immunoglobulin heavy chain component. LC-MGUS may show progression to idiopathic Bence Jones proteinuria, light chain PCM, AL amyloidosis, or light chain deposition disease [3]

Etiology

No specific cause of Non-IgM MGUS has been identified. However, the disease may be associated with some non-malignant disorders such as connective tissue disorders, peripheral neuropathies, dermatological diseases such as acquired C1 esterase inhibitor deficiency (angioedema), endocrine diseases, and liver infections such as hepatitis C virus infection liver and HIV liver disease [3][4][2]

Epidemiology

MGUS is found in approximately 2% to 3% of adults over age 50 and in approximately 5% of adults older than the age of 70. MGUS is more common in men than in women (- 1.5:1) and 2-fold to 3-fold more common in African Americans compared to Caucasians. Non-IgM MGUS represents up to 85% of MGUS cases; IgM MGUS represents up to 15% of MGUS cases [3][4]

Pathophysiology

The clonal plasma cells producing non-IgM MGUS reside in the bone marrow (BM). These cells harbor somatic hypermutation of the variable regions and are class-switched. The majority of non-IgM MGUS are IgG, followed by IgA, bi-clonal, and IgD [1][2]

History and Physical

The majority of non-IgM MGUS patients are asymptomatic. According to the WHO 2017, Non-IgM MGUS diagnosis is based on 3 diagnostic criteria:

  1. Serum monoclonal protein less than 30 g/L 
  2. Less than 10% clonal plasma cells in the BM 
  3. The absence of CRAB symptoms suspicious for PCM

Non-IgM MGUS is usually diagnosed as an incidental finding on protein electrophoresis performed as part of an evaluation for disorders or disease presentation of peripheral neuropathy, vasculitis, hemolytic anemia, skin rashes, hypercalcemia, elevated erythrocyte sedimentation rate. Non-IgM MGUS is generally not considered a neoplastic process, with an annual risk of progression of 1%. Non-IgM MGUS may show progression to PCM, solitary plasmacytoma or amyloidosis. Two important factors influence non-IgM MGUS progression. The first is the size and type of M protein, and the second is the level of immunoglobulin (less than 5 g/L and greater than 25 g/L) [5][1][2]

Evaluation

Non-IgM MGUS needs a thorough set of investigations to exclude this disease entity from the other plasma cell neoplasms. Investigations should include complete blood count (CBC), bone marrow aspirate/biopsy (BMA/BMB), immunohistochemical analysis (IHC), serum calcium and creatinine, serum protein electrophoresis and immunofixation, urine protein electrophoresis and immunofixation, serum serum free light chains (FLC) assay, quantitation of immunoglobulins, bone survey of skull, spine, and pelvis (plain x-ray, computerized tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)), immunophenotyping utilizing flowcytometry, and/or genetic testing.[5][1][5]

CBC/peripheral smear is usually normal. However, some cases may show rouleaux formation. BMB usually shows 3% to 5% mature plasma cells (less than 10%) evenly scattered or in occasional small clusters. CD138 is useful in highlighting these plasma cells in the BMB. IHC of the plasma cells for kappa and lambda will demonstrate monoclonal restriction. MGUS is characterized by the presence of a monoclonal (M) protein which is produced by clonal plasma cells and detected by SPEP, UPEP and/or immunofixation of the serum and urine. Immunophenotyping shows monoclonal plasma cells that are CD38+ (bright) cells with an aberrant CD56 population (may also be negative). Molecular testing for Non-IgM MGUS has shown that this disease entity usually shows a normal karyotype because of the relatively small number of plasma cells. Some patients show chromosomal alterations of PCM that include: t(11;14), t(4;14), t(14;16), deletions of 13q and hyperdiploid. No clinical correlation for these genetic alterations has been found in non-IgM MGUS [6][1]

Differential Diagnosis

It is important to distinguish non-IgM MGUS from other advanced plasma cell neoplasms since these diseases will require a different management approach. The differential diagnosis of non-IgM MGUS include:

  • PCM (smoldering or symptomatic): Any patient with a non-IgM serum monoclonal protein greater than or equal to 30 g/L or with greater than or equal to 10% clonal plasma cells in the bone marrow should not be diagnosed as non-IgM MGUS. Many physicians consider smoldering PCM as a transition stage between non-IgM MGUS and symptomatic PCM. Smoldering PCM is distinguished from MGUS based on the size of the M protein and the percentage of clonal plasma cells in the bone marrow. Smoldering PCM is distinguished from symptomatic PCM by the presence of CRAB symptoms [2]
  • Waldenström macroglobulinemia (smoldering or symptomatic): WM is a distinct clinicopathologic disorder that shows lymphoplasmacytic lymphoma (LPL) in the bone marrow and an IgM monoclonal gammopathy. Symptoms include blood hyperviscosity, lymphadenopathy and/or splenomegaly. The WHO (2017) diagnostic criteria of WM include[2]:
  1. IgM monoclonal gammopathy
  2. Clonal plasma cells less than 10%
  3. Absence of end-organ damage (CRAB symptoms)
  4. Absence of symptoms or signs of amyloidosis
  • Monoclonal gammopathy of renal significance: This disease entity is diagnosed when the patient has diagnostic criteria for MGUS as well as renal insufficiency and monoclonal immunoglobulin deposits in the kidney by immunofluorescence [7]
  • Light chain smoldering multiple myeloma (idiopathic Bence Jones proteinuria): The diagnostic criteria of LC-SMM include:
  1. Monoclonal light chains in the urine (Bence Jones proteinuria)
  2. No immunoglobulin heavy chain expression in the serum or urine
  3. No symptoms of PCM, WM, or amyloid light chain amyloidosis
  • Primary (amyloid light chain) amyloidosis and light chain deposition disease: This entity of plasma cell neoplasms is associated with the pathologic deposition of monoclonal light chains in tissue. The diagnostic criteria include the presence of amyloid in tissue and evidence of plasma cell neoplasm.
  • B cell lymphoproliferative disorder

Prognosis

Non-IgM MGUS is considered a preneoplastic condition with an annual risk of progression of approximately 1%. Risk of progression is increased when M protein greater than or equal to 15 g/L and with abnormal free light chain ratio. Non-IgM MGUS does not require treatment. However, the management of patients with non-IgM MGUS requires an understanding of the risk of progression of the disease. Generally, close follow-up is recommended for these patients. Most physicians believe that all non-IgM MGUS patients should undergo clinical examination and laboratory evaluation for disease progression annually [5]Some physicians prefer to risk stratify patients based on the following criteria:

  1. Serum monoclonal protein level greater than or equal to 15 g/L
  2. Non-IgG MGUS (i.e., IgA, IgM, and IgD MGUS)
  3. Abnormal serum free light chain ratio

Patients with 3 risk factors are categorized as high-risk MGUS; patients with 2 risk factors are categorized as high-intermediate risk MGUS. Patients with one risk factor are categorized as low-intermediate risk MGUS. Patients with no risk factors are categorized as low-risk MGUS. Despite close observation, some non-IgM MGUS patients may show progression to PCM abruptly [6][2]

Enhancing Healthcare Team Outcomes

MGUS is best managed by a multidisciplinary team that includes nurses. These patients need long term follow up because of the potential to numerous complications.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Monoclonal Gammopathy Of Undetermined Significance (MGUS) - Questions

Take a quiz of the questions on this article.

Take Quiz
What is the most probable diagnosis in a patient with an elevated immunoglobulin spike on serum electrophoreses but no other symptoms?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient is diagnosed with monoclonal gammopathy of unclear significance (MGUS). The patient returns for follow up, and his labs have changed with creatinine 2.1 mg/dL, potassium 4.0, calcium 12.5 mg/dL, and triglycerides of 215 mg/dL. He reports puffy eyes and foamy urine. On exam, he has anasarca, so concerns are for multiple myeloma and nephrotic syndrome. Urine protein/creatinine ratio is 14:1. Select the correct treatment of his lipids.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What are the risks of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) progressing to multiple myeloma (MM) per year?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the rate of progression of non-IgM monoclonal gammopathy of uncertain significance (MGUS) to more advanced disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following factors is associated with increased risk of progression in non-IgM monoclonal gammopathy of uncertain significance (MGUS)?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Monoclonal Gammopathy Of Undetermined Significance (MGUS) - References

References

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)., Dhodapkar MV,Sexton R,Waheed S,Usmani S,Papanikolaou X,Nair B,Petty N,Shaughnessy JD Jr,Hoering A,Crowley J,Orlowski RZ,Barlogie B,, Blood, 2014 Jan 2     [PubMed]
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance., Kyle RA,Larson DR,Therneau TM,Dispenzieri A,Kumar S,Cerhan JR,Rajkumar SV,, The New England journal of medicine, 2018 Jan 18     [PubMed]
Monoclonal gammopathy of undetermined significance., Kyle RA,Rajkumar SV,, British journal of haematology, 2006 Sep     [PubMed]
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant., Leung N,Bridoux F,Hutchison CA,Nasr SH,Cockwell P,Fermand JP,Dispenzieri A,Song KW,Kyle RA,, Blood, 2012 Nov 22     [PubMed]
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma., Rajkumar SV,Dimopoulos MA,Palumbo A,Blade J,Merlini G,Mateos MV,Kumar S,Hillengass J,Kastritis E,Richardson P,Landgren O,Paiva B,Dispenzieri A,Weiss B,LeLeu X,Zweegman S,Lonial S,Rosinol L,Zamagni E,Jagannath S,Sezer O,Kristinsson SY,Caers J,Usmani SZ,Lahuerta JJ,Johnsen HE,Beksac M,Cavo M,Goldschmidt H,Terpos E,Kyle RA,Anderson KC,Durie BG,Miguel JF,, The Lancet. Oncology, 2014 Nov     [PubMed]
Inherited genetic susceptibility to monoclonal gammopathy of unknown significance., Weinhold N,Johnson DC,Rawstron AC,Försti A,Doughty C,Vijayakrishnan J,Broderick P,Dahir NB,Begum DB,Hosking FJ,Yong K,Walker BA,Hoffmann P,Mühleisen TW,Langer C,Dörner E,Jöckel KH,Eisele L,Nöthen MM,Hose D,Davies FE,Goldschmidt H,Morgan GJ,Hemminki K,Houlston RS,, Blood, 2014 Apr 17     [PubMed]
The 2016 revision of the World Health Organization classification of lymphoid neoplasms., Swerdlow SH,Campo E,Pileri SA,Harris NL,Stein H,Siebert R,Advani R,Ghielmini M,Salles GA,Zelenetz AD,Jaffe ES,, Blood, 2016 May 19     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pharmacy-Pharmacotherapy. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pharmacy-Pharmacotherapy, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pharmacy-Pharmacotherapy, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pharmacy-Pharmacotherapy. When it is time for the Pharmacy-Pharmacotherapy board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pharmacy-Pharmacotherapy.